Actualités
Emploi

New research team & group leader

Laboratoire d’Excellence MAbImprove - Institut de Recherche en Cancérologie de Montpellier :
 
Call for proposals 2015 : New research team  & group leader
 
The Laboratoire d’Excellence (LabEx) MAbImprove (http://mabimprove.univ-tours.fr/) is proud to launch its first call for proposals to welcome a new research team or group leader. This call is a partnership with the Institut de Recherche en Cancérologie de Montpellier (IRCM, www.ircm.fr) and will be devoted to therapeutic antibodies against cancer. Both junior and senior group leader proposals will be considered. 
 
The MAbImprove initial support package will provide the laureate with up to 600 k¤ including a 3-years group leader salary (in case of laureate without permanent position), a 3-years post-doctoral fellow salary, a PhD student and starting grant.
 
MAbImprove is a 2-sites “Laboratoire d’excellence” (LabEx) dedicated to therapeutic antibodies (http://mabimprove.univ-tours.fr/). It was launched in 2011 with a program based on the clinical use of antibodies and which can be summarized in a few words “improved antibodies, improved development and improved used”. MAbImprove is organized in 5 WPs from clinical pharmacology, experimental pharmacokinetics and pharmacodynamics to new targets evaluation and innovative technologies. Based on a partnership between the Universities of Tours and Montpellier, associated with INSERM, the CNRS, the INRA, the University Hospital of Tours and the Comprehensive Cancer Hospital of Montpellier (ICM), MAbImprove LabEx federates 14 research teams and more than 200 researchers. It is based on the complementarity of both sites, as well as on a national network of academic teams involved in the project and numerous pharmaceutical and biotechnology companies directly affected by fallout from the project.  IRCM is presently composed of 12 research teams organized in two mains programs: (i) therapeutic antibodies to target cancer: innovation, design & biological response; (ii) phenotypic, genetic, epigenetic and signaling plasticity of solid tumors: from discovery to personalized medicine.
 
More informations :  angry
 
 


Retour à la liste générale

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés